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(Correspondence should be addressed to P Ciana; Email: paolo.ciana@unimi.it)AbstractSex hormones modulate proliferation, apoptosis, migration, metastasis and angiogenesis in
cancer cells influencing tumourigenesis from the early hyperplastic growth till the end-stage
metastasis. Although decades of studies have detailed these effects at the level of molecular
pathways, where and when these actions are needed for the growth and progression of hormone-
dependent neoplasia is poorly elucidated. Investigation of the hormone influences in
carcinogenesis in the spatio-temporal dimension is expected to unravel critical steps in tumour
progression and in the onset of resistance to hormone therapies. Non-invasive in vivo imaging
represents a powerful tool to follow in time hormone signalling in the whole body during tumour
development. This review summarizes the tools currently available to follow hormone action in
living organisms.Endocrine-Related Cancer (2011) 18 R41–R51Introduction
Neoplastic transformation is a highly regulated and
ordered process, where a sequela of biological events
leads cancer cells to acquire specific phenotypic traits
necessary to escape the strong selective pressure of
the host tumour surveillance (Merlo et al. 2006). In the
current view, cancer development is more related to
the coordinated generation of a new tissue rather than
to the mere disruption of a biological program; the vast
network of intracellular and extracellular signals
involved in carcinogenesis are well coordinated in
time and are characterized by several discrete steps
leading to the acquisition of specific cell functions,
which are commonly observed during cell transfor-
mation (Hanahan & Weinberg 2000). The attempts to
decode the order and timing for the genetic changes
typically associated with carcinogenesis were only
partially successful; this led to formulate the
hypothesis that the process is redundant involving a
large variety of epigenetic/genetic mutations occurring
in oncogenes/oncosuppressors (Esteller 2006), which
cannot be directly associated to specific tumour stagesEndocrine-Related Cancer (2011) 18 R41–R51
1351–0088/11/018–R41 q 2011 Society for Endocrinology Printed in Great(Hanahan & Weinberg 2000). In hormone-related
carcinogenesis, endogenous and exogenous hormones
influence a multiplicity of cell functions. Dysregula-
tion of sex hormone-receptor signalling occurs in the
tumourigenesis of breast, endometrial, ovary, prostate
and testis, where oestrogens, progestin and androgens
have been shown to modulate the proliferation of
epithelial cells, thus increasing the probability of
accumulation of genetic errors. Contribution of sex
hormones to the malignant phenotype, besides the
induction of the initial hyperplasia, is still elusive.
A multidisciplinary approach combining in vivo
imaging with system biology is expected to add
novel insights on the temporal characterization of the
changes stimulated by the hormones, leading to the
progression of hormone-related cancers.The influence of steroid hormone action
on tumour growth and progression
Sex hormones such as oestrogens, progestins and
androgens are hydrophobic ligands, which bind toBritain
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intracellular receptors (IRs). These receptors can be
activated by the cognate ligand or in its absence, by
post-translational modifications elicited through the
intracellular signalling of membrane receptors (Weigel
& Moore 2007, Stanisic´ et al. 2010). Upon ligand
binding, receptor activation occurs via diversified
pathways involving genomic or non-genomic
mechanisms (Migliaccio et al. 2007), i.e. the activated
receptor may directly bind to the DNA-responsive
elements in the regulatory regions of these genes or
may influence other pathways involved in cell
proliferation by interfering with specific proteins in
the cytoplasm (e.g. AKT/PI3K) or in the nucleus (e.g.
NFkB, AP-1 and SP-1). Co-activators, co-repressors
and integrators interact with IRs to mediate their
transcriptional activity; the expression and activity of
these co-regulators may be tissue-specific and in turn
can be modulated by cell metabolism. In the whole
organism, co-regulators integrate positional infor-
mation with signal transduction to produce in each
cell a selective modulation of steroid receptor target
genes. In some target cell, including endocrine-related
tumour cells, the activated receptor is able to stimulate
G1/S-phase transition through the G1 restriction point
by inducing the expression of specific cell cycle
regulators, such as c-myc, c-fos, c-jun and cyclinD1
(Butt et al. 2005, Lamont & Tindall 2010). Stimulation
of these mitogenic pathways eventually promotes the
hyperplastic growth of epithelial cells in reproductive
tissues; however, this proliferative induction does not
entail for the full carcinogenic potential of a
dysregulated steroid hormone signal: indeed, steroid
hormones modulate apoptosis, promote migration,
metastasis and angiogenesis functions in tumour cells
(Kaarbø et al. 2007, Lewis-Wambi & Jordan 2009,
Sarker et al. 2009, Dondi et al. 2010). Current
hypothesis propose that the influence of hormones
extends throughout the carcinogenesis process. In
clinical experience, this is well exemplified by the
fact that anti-hormone drugs are active at different
stages preventing the early tumour onset (William
et al. 2009) or metastasis formation (Boccardo et al.
1999, Howell et al. 2005). How the hormone signalling
is integrated in the process of carcinogenesis and which
is the contribution to the generation of the transformed
phenotype is only partially elucidated; it may be
expected that non-invasive in vivo imaging tools
allowing the investigation of molecular events in
time might help filling this gap. This review aims at
illustrating the in vivo imaging methodologies avail-
able now (supplementary data, see section on
supplementary data given at the end of this article)R42and applicable to the measurement in real time, of:
i) receptor expression, ii) hormone production, iii)
receptor activation and iv) receptor-dependent modu-
lation of specific cellular pathways.Molecular imaging of steroid receptor
expression
Regulation of steroid receptor expression is governed
by complex mechanisms (Stanisic´ et al. 2010),
including usage of multiple promoters (Sasaki et al.
2003), generation of different splicing variants,
regulation of mRNA stability (Hirata et al. 2003) and
receptor proteolysis (Alarid 2006). These mechanisms
were found, in some case, to be deregulated in tumour
cells, although the existence of a coordinated action
modulating the receptor expression during hormonal
tumourigenesis has not been investigated. The
dynamic view offered by imaging provides a unique
insight on the interrelation between hormone receptor
regulation and tumour insurgence and progression.
This might contribute, for example, to gain information
on the mechanisms underlying the arousal of hormone-
resistant subclones in patients (a tumour evolution that
worsen prognosis and invariably occurs in chronic
treatments with hormonal therapy). In a significant
proportion of such patients, for unknown reasons, a
down-regulation of receptor expression is observed
(Kuukasja¨rvi et al. 1996, Chen et al. 2004, Sabnis et al.
2008, Musgrove & Sutherland 2009, Zilli et al.
2009). Imaging gives the possibility to isolate tumours
at a precise stage when this event occurs, and hence
allows investigating which signalling pathways are
directly linked to receptor down-regulation. Steroid
receptor expression in tumours is measurable with
positron emission tomography (PET) and single
photon emission computed tomography (SPECT)
(supplementary data, see section on supplementary
data given at the end of this article) using oestrogens,
progestins and androgens chemically labelled with
77Br (Katzenellenbogen et al. 1981, McElvany
et al. 1982), 123I (Zielinski et al. 1989, Rijks et al.
1998), 18F (Kiesewetter et al. 1984, Liu et al. 1992,
Katzenellenbogen et al. 1997, Jonson & Welch 1998)
radioisotopes (for a review on nuclear imaging see de
Vries et al. (2007) and Hospers et al. (2008)). PET
analysis provides an accurate measurement of receptor
expression that correlates with the more classical
immunohistochemical-based quantification of receptor
content (Peterson et al. 2008). These radiotracers have
been largely applied in clinics particularly to the
selection of patients with a chance to respond to
hormonal therapy (for a review see Dunphy & Lewiswww.endocrinology-journals.org
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of hormone dependency of endocrine tumour model
have not yet been exploited; it has to be considered the
facts that these methodologies normally require
expensive instrumentation and, most of the time, also
a cyclotron, therefore are restricted to a relatively small
number of laboratories. Recently, Cerenkov radiation
imaging was presented as a novel concept, allowing the
use of conventional optical imaging devices for the
detection of radiotracers, thus opening new perspective
for the in vivo detection of radiolabelled hormones
(Robertson et al. 2009, Hu et al. 2010, Ruggiero et al.
2010, Spinelli et al. 2010).Molecular imaging of hormone production
In the central nervous system as well as in the
periphery, multiple mechanisms govern the production
and the metabolism of steroid hormones. Dysregula-
tion of this network of signalling pathways contributes
to endocrine tumourigenesis; indeed, drugs that target
steroid hormone synthesis or metabolism are among
the most efficacious for the treatment of hormone-
dependent breast and prostate cancers (e.g. aromatase
inhibitors and GnRH analogues). Hormones, metab-
olites and catabolites are able to bind and activate
different types of receptors that fine-tune the homeo-
stasis of target tissues. A well-characterized example is
the prostate tissue, where a network of hormone signals
controls the tissue physiology and prevents tumour-
igenesis. In the prostate, dihydrotestosterone (DHT)
controls the physiological proliferation, while dysre-
gulation of this signal eventually promotes prostate
cancer cell growth. The inactive androgen, testoster-
one, is either reduced to the active form DHT or
aromatized to 17b-oestradiol (E2); DHT and E2 bind
androgen receptor (AR) and oestrogen receptor (ER)s
respectively, with different and sometime opposing
effects on the prostate target cells (Bilin´ska et al. 2006,
Carruba 2007, Ellem & Risbridger 2010). Furthermore,
DHT can also be reduced to 5a-androstane-3b,17b-
diol (3b-Adiol), a metabolite which binds and activate
preferentially the ERb isoform (Imamov et al. 2004,
Guerini et al. 2005), but not AR, counteracting DHT
action on the growth of the normal prostate (Weihua
et al. 2002) and on the proliferation, migration and
metastasis of prostate cancer cells (Weihua et al. 2002,
Dondi et al. 2010). When and how perturbation of this
complex hormone balance occurs during prostate
tumourigenesis is not easy to address experimentally.
We need to develop appropriate tools to study the
dynamics of ligand or metabolite production in the
whole organism. Imaging the activity of specificwww.endocrinology-journals.orgenzymes involved in steroidogenesis or the presence
of certain hormones or their metabolites in a tissue
could be very helpful to dissect temporarily each event.
Some of the current methodologies based on reporter
systems may be adapted to the measurement of
the synthesis of ligands for a given steroid receptor
in vivo. Two types of sensors were developed to
measure the hormone production in vivo and both rely
to the ability of the ligand to bind and transcriptionally
activate the steroid receptor: i) genetic two-hybrid
system, where the receptor ‘ligand-binding domain’
(LBD) is fused to the Gal4 DNA binding domain and
ii) an intramolecular folding system based on reporter
genes fused to the receptor LBD. The two-hybrid
system strategy is based on the ligand-dependent
activation of the Gal4–LBD fusion protein, which in
turn induces the transcription of a reporter gene (e.g.
b-galactosidase) driven by a GAL4-responsive
promoter; in this system, the amount of reporter
protein synthesized is directly proportional to the
hormone contents in a given tissue (Mata de Urquiza &
Perlmann 2003). Transgenic reporter mice generated
with these types of biosensors were demonstrated to be
useful tools to investigate the production of endogen-
ous retinoids or thyroid hormones during embryo
development and in mature mice (Solomin et al. 1998,
de Urquiza et al. 2000, Quignodon et al. 2004). The
second strategy is based on a fusion protein containing
the hormone receptor LBD which splits luciferase
polypeptide in two parts; after the hormone binding,
an intramolecular folding occurs and reconstitutes the
luciferase activity. These systems were proven to be
helpful for measuring the activity of selective oestrogen
receptor modulator in cell lines (Paulmurugan &
Gambhir 2006, Paulmurugan et al. 2009). These
sensors, if expressed ubiquitously with appropriate
reporter genes (Weissleder & Pittet 2008), allow for
the in vivo imaging of hormone production.Molecular imaging of steroid receptor
activity
A major limitation in the studies measuring ligand
and/or receptor distribution within the body is the lack
of any insight on the extent to which the receptor is
activated and contributes to the cell phenotype. Indeed,
the amount of hormones in the blood does not have a
prognostic value in clinic and is usually not indicative
of the state of the activity of the receptor in the tumour;
mechanisms such as receptor desensitization, ligand-
independent activation and tissue-specific interaction
with co-regulators are well known to strongly modulate
sex-steroid signalling pathways. Thus, independent ofR43
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important to identify the time points when the receptor
activity is actually required or lost during endocrine-
related cancer progression; this information can be
provided by in vivo imaging. A number of systems
have been developed for measuring steroid-receptor
activity in vivo, of which some of them were
specifically designed for in vivo imaging. Since sex-
steroid receptors are transcription factors, receptor
activation is usually measured for its ability to induce
the transcription of a reporter gene. Reporter systems
of this type were applied to the production of
transgenic reporter mice successfully obtained by our
group (Ciana et al. 2001) and other laboratories
(Lemmen et al. 2004, Hsieh et al. 2005), thanks to
the use of an appropriate technology to prevent the
position effects linked to the transgenesis procedure
(Maggi et al. 2004). In these models, it is possible to
measure the state of ER and AR activation in all mouse
tissues. Bioluminescence imaging (supplementary
data, see section on supplementary data given at the
end of this article) applied to these reporter miceA
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physiology (Ciana et al. 2003, 2005, Lemmen et al.
2004) and in cancer biology (Fig. 1, Lyons et al. 2006,
Hsieh et al. 2007); in these works, steroid receptor
activation was evaluated in the tumours of living mice,
and was used as a marker to identify those animals that
after hormone ablation were capable of sustaining
tumour growth. Another strategy to measure receptor
activity in vivo was developed by O’Malley’s group
that generated the so called ‘indicator’ mouse models,
allowing the measurement of receptor expression and
activity simultaneously, in vivo (Han et al. 2005,
2009, Ye et al. 2005). ‘Indicators’ are mice genetically
engineered with bacterial artificial chromosome (BAC)
which carries a genomic region of a nuclear receptor
(ER, AR or PR) with the inserted GAL4 DNA-binding
domain and encoding for a fusion protein (ER–GAL4,
AR–GAL4 or PR–GAL4) that displays the same tissue
distribution of the endogenous receptor; in addition,
each BAC also carries a reporter system for the nuclear
receptor activity. The receptor/GAL4 fusion protein
once expressed becomes activated and binds to theB Ex vivo imaging of
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production of a green fluorescence protein (GFP).
Thus, GFP level in the indicator mouse is proportional
to the receptor expression and activation at the same
time. Unfortunately, the GFP used in the generation of
these models is not an ideal reporter for in vivo imaging
(mainly due to the wide overlapping of the peak of the
fluorescence emitted by the GFP and the autofluores-
cence peak naturally present in the tissues). Also in this
case, the appropriate choice of the reporter gene used
in the indicator mouse would allow the in vivo imaging
of receptor expression and activity.Molecular imaging of signalling pathways
activated by the hormone
Liganded or unliganded modulation of the steroid
receptor results in the activation or inhibition of
intracellular circuitry translating the hormonal
message into phenotypic effects. Sex-steroid receptor
activation in hormone-dependent neoplasia modulates
a broad range of key pathways for tumourigenesis,
including those governing apoptosis, proliferation and
angiogenesis.
Apoptosis
In the war against cancer, one of the major problems
arises from the changes of the tumour phenotype
in terms of sensitivity to proapoptotic treatments
(Shankaranarayanan et al. 2009). In hormone-dependent
tumours, sex-steroid receptors are known to differen-
tially regulate apoptotic pathways depending on the
tumour stage or the cellular context (Lewis-Wambi &
Jordan 2009); in vivo imaging could help to identify the
tumour stage at which this modulation occurs and to
correlate it with the sensitivity of the cells to apoptotic
stimuli. A wide array of non-invasive imaging
techniques has been developed so far to follow the
molecular events specifically occurring during apop-
tosis. It is possible, for example, to measure caspases
activation by using luminescent, fluorescent or radio-
labelled substrates carrying a caspase recognition
sequence (e.g. Asp-Glu-Val-Asp: DEVD) or to
measure expression of annexin V apoptotic marker
with fluorescent/radioactive probes. Most of these
imaging tools are currently used in the development
of new anti-cancer treatment and in clinical studies to
assess treatment responses (Kurihara et al. 2008).Proliferation
The mechanism underlying stimulation of cancer cell
proliferation by sex hormones has been investigated towww.endocrinology-journals.orgthe molecular details in about four decades of research
in animals and cultured cells. However, there are
preclinical (Zhao et al. 1992) and clinical data (Clarke
et al. 1997, Anderson 2002, Clarke 2004) challenging
the simplest view that hormones are always behaving
as inducer of cell proliferation. These studies suggest
that, during tumour development, the sensitivities of
neoplastic cells to the hormones vary in terms of
proliferative response; thus, it remains unclear whether
the proliferative effects of the hormone is requireddur-
ing specific stages or throughout whole tumour
progression. Non-invasive in vivo imaging may
provide novel insights into this issue allowing to
follow the proliferative activity of every single tumour
during its growth and metastasis and to evaluate its
sensitivity to hormones at every different stage.
Nuclear, magnetic resonance and optical imaging
tools are used to measure cell proliferation in vivo.
Nuclear imaging of proliferation is based on probes
designed to measure in cancer cells: i) the accelerated
DNA synthesis, e.g. nucleotide analogues like
[11C-methyl]TdR, 2 0-deoxy-2 0-fluoro-1-b-D-arabino-
furanosyl)-thymine (FMAU), FLT (1-(2 0-deoxy-2 0-
fluoro-b-D-arabinofuranosyl-uracil)-bromouracil (FBAU),
[18F]fluorothymine) or ii) the accelerated cellular
metabolism, e.g. labelled sugar, 18F-fuorodeoxyglu-
cose (FDG), amino acid (L-[11C-methyl]-methionine
and L-[1-11C]tyrosine ([18F]-fluorocholine) or lipids
([18F]-fluoroethilcholine and [11C]-choline). PET
evaluation of uncontrolled proliferation in hormone-
sensitive breast cancers was applied to evaluate their
response to chemotherapy (Sun et al. 2005, Pio et al.
2006, Kenny et al. 2007, Kim et al. 2007) and for
tumour staging (Kwock et al. 2006, Laprie et al. 2008).
Optical imaging tools, including molecular probes
(selectively binding the tumour cells) or reporter genes
were developed to label tumour growth and are
currently used in preclinical studies to localize as little
as 100–1000 xenografted cancer cells in animal
models; these systems provide a quantitative measure
of cancer growth and metastasis and hence found
useful for screening compounds with anti-cancer
properties. Some reporter system was also applied to
the generation of transgenic reporter mice in which it is
possible to directly measure mitogenic pathways in the
animal tissues. Uhrbom et al. 2004 have generated a
transgenic mouse expressing luciferase only when the
Rb pathway is inactivated and the transformed cells
underwent uncontrolled proliferation; activation of this
biosensor allows the detection of sporadic tumour
arousal and to follow the neoplastic growth in time in
the whole body by using bioluminescence in vivo
imaging. A further refinement of this model refers toR45
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which luciferase is a measure of all mitogenic signals
in the body (Piaggio G, Maggi A, Ciana P, manuscript
in preparation). In this mouse model, it is possible to
detect proliferation not only in the growing tumour but
also in pre-malignant lesion and in the normal tissues
where proliferation occurs as a physiological response
to tumour growth (e.g. immune system responses,
vessel formation and stroma cells responses). This
model can also be particularly relevant in drug
development to evaluate toxicity of compounds
interfering with the normal homeostatic proliferation
found in body tissues (e.g. bone marrow toxicity).Angiogenesis
When cancer grows beyond 1–2 mm3 in diameter,
there is a requirement for new blood vessels to supply
nutrients and oxygen. For endocrine cancers, it is still
largely debated whether sex hormones have a role in
this neo-angiogenic process; indeed, there are evidence
for a direct transcriptional control of the hormones on
vascular endothelial growth factor (VEGF) and avb3
integrin genes, two key players in neo-angiogenesis
(Bogin & Degani 2002, Buteau-Lozano et al. 2002,
Hood & Cheresh 2002). However, no mechanistic
hypothesis into this hormone control has been
proposed yet. It would be interesting, for example, to
evaluate the role of endocrine signals on the
mobilization, recruitment and differentiation of endo-
thelial progenitor cells (bone marrow-derived or
resident) and on the subsequent new vessel formation.
Although some system have been devised to label
progenitor stem cells for imaging their fate in the body
(Schroeder 2008) and to evaluate the associated neo-
angiogenesis, to the best of our knowledge, there has
been no report applying imaging technology for the
characterization of sex hormone signalling on new
vessel formation. Several imaging modalities can be
used to visualize neo-angiogenesis with probes
detecting VEGF or avb3 integrins expression, e.g.
PET imaging with radiolabelled antibodies against
VEGF (Nagengast et al. 2007) or ultrasound imaging
of VEGF/VEGF monoclonal antibody conjugated
with microbubbles (Korpanty et al. 2007, Willmann
et al. 2008). Since avb3 integrins recognize specific
component of the extracellular matrix containing
the arginine-glycine-aspartic acid (RGD), RGD-
containing peptides have also been developed
as targeting ligands for imaging neo-vasculature
formation in tumours; indeed, radiolabelled RGD-
containing compounds such as (18)F-Galacto-RGD or
(99m)Tc-NC100692 have been successfully used forR46PET analysis of the neo-angiogenesis associated to
squamous cell carcinoma or breast cancer (Bach-
Gansmo et al. 2006, Beer et al. 2007). Biolumines-
cence modality is also often applied for the detection of
new vessel formation (Fukumura et al. 1998, Snoeks
et al. 2010); in this research line, an interesting
transgenic mouse model was recently developed as a
tool to follow the activation of the hypoxia-inducible
factor1a (Hif1a). Hif1a is a transcription factor
turning on the neo-angiogenesis programme when
cells are under low-oxygen conditions. In this work,
Safran et al. reported the generation of a reporter
mouse ubiquitously expressing a bioluminescent
reporter consisting of the firefly luciferase fused to a
region of Hif1a that is sufficient for oxygen-dependent
degradation. In all tissues of this mouse, any hypoxic
condition induces an increased bioluminescent
emission, which can be detected by optical imaging
(Safran et al. 2006).Conclusions and perspectives
There is only a limited knowledge on the dynamic
influence of sex steroid hormones on the development
and progression of endocrine-related cancers. New
tools, which would allow the investigation of molecu-
lar events in the spatio-temporal dimension, are
required to follow the steroid hormone message from
its circulation in the body till the activation of
intracellular signalling pathways in the tumour itself
and in the normal tissues. In vivo imaging comprises a
cluster of technologies allowing the measurement of
biological events with respect to time and in the whole
animal, information that is particularly relevant for
hormonal carcinogenesis also in consideration of the
systemic effects of hormones and the complex network
of signals going back-forward from CNS to the
reproductive tissues. Each different imaging modality
presents pros and cons which currently limits the
analysis in terms of sensitivity, resolution and type
of information provided on the biological events
(Massoud & Gambhir 2003; supplementary data, see
section on supplementary data given at the end of this
article). To overcome these limitations, a wealth of
novel systems and novel instrumentations allowing the
integration of different imaging modalities (Stell
et al. 2007a, Tian et al. 2008, Lee & Chen 2009)
have been proposed, including PET/CT (Cherry 2009),
PET/fluorescence/bioluminescence (Kesarwala et al.
2006), PET/MRI (Sauter et al. 2010) and other
combinations of technology, which integrate molecular
information with morphological information and
uncouple spatial resolution with higher degree ofwww.endocrinology-journals.org
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Further advancement in the field is also expected in the
way probes and biosensors are designed to widen the
list of molecular events that can be monitored by
in vivo imaging (Stell et al. 2007b, Pysz et al. 2010).
Among them, fluorescence resonance energy transfer
(FRET) and bioluminescence resonance energy
transfer (BRET) are promising technologies which
have already opened up new avenues of measuring
protein–protein and ligand–receptor interactions,
membrane receptor activation and calcium signalling.
Several methodologies based on FRET/BRET biosen-
sors have been applied to the study of the key compo-
nents of the hormone signalling, including ligand
binding (Michelini et al. 2004, De et al. 2005), receptor
dimerization (Schaufele et al. 2005, Powell & Xu
2008) and recruitment of co-regulators (Koterba &
Rowan 2006, Ozers et al. 2007). These methods have
not been fully developed for the study of sex hormone
signal in vivo; however, we expect that BRET and
FRET, when combined with intravital microscopy or
optical detection systems, will significantly improve
the spatio-temporal analysis of hormonal pathways
from single cell to a whole body resolution. More
information are also expected to come from the
application of imaging onto cancer stem cell field
that already gave promising results (Hong et al. 2010);
imaging might help answering several open questions
about the role of sex hormones on the fate of cancer
stem cells (LaMarca & Rosen 2008). This is a rather
important issue, which needs clarification to under-
stand the mechanisms underlying the early events
occurring during hormonal transformation and in the
establishment of resistance.
Obviously, the information provided by in vivo
imaging alone cannot be sufficient to generate a
comprehensive representation of the molecular
pathways involved in tumour development; in this
sense, in vivo imaging represents a good way to identify
tumour stages at which changes in selected molecular
pathways (e.g. sex-hormone receptor signals) occur,
before they produce evident consequences on the
phenotype of transformed cell. Imaging analysis of
different aspects of the steroid hormone signalling is
now expected to drive classical molecular genetics
and genomic studies towards the characterization
of specific steps during carcinogenesis, when the genetic
reprogramming actually occurs. Hopefully, the descrip-
tion of the molecular pathways involved in these steps
will help identifying unique marker signatures of
neoplasia progression and inspire the design of new
therapeutic strategies for hormone-related cancers
and to overcome the problem of drug resistance.www.endocrinology-journals.orgSupplementary data
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